Junto Health

juntohealth.org

At Junto Health, we believe that the healthcare ecosystem needs to adopt open innovation practices and co-development models to successfully implement, and scale, new technology. We also know that sometimes you need a little help from your friends, so we have curated an exclusive network of members representing the best providers, payors, tech companies, pharma, investors, policy advisors, and startups.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MedTech

BIO-ISAC AND NEW YORK METRO INFRAGARD MEMBERSHIP ALLIANCE ANNOUNCE PARTNERSHIP

NY Metro InfraGard | April 28, 2022

news image

The Bioeconomy Information Sharing and Analysis Center (BIO-ISAC) and New York Metro InfraGard Members Alliance® (NYM-IMA) today announced a partnership to address threats unique to the bioeconomy and enable coordination among stakeholders to facilitate a robust and secure industry. BIO-ISAC is a critical resource for cyber threat detection, prevention, protection, response, recovery and resilience in the bioeconomy. It helps spur the development and evaluation of defensive to...

Read More

Industry Outlook

SANGAMO THERAPEUTICS AND CHROMA MEDICINE ANNOUNCE OPTION AND LICENSE AGREEMENT TO EVALUATE AND DEVELOP ZINC FINGER PROTEINS FOR EPIGENETIC EDITING

Businesswire | July 21, 2023

news image

Sangamo Therapeutics, Inc. a clinical-stage genomic medicine company and Chroma Medicine, Inc. a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced they have entered into a research evaluation, option and license agreement to develop epigenetic medicines leveraging zinc finger proteins (ZFPs) for sequence-specific DNA recognition. Over the course of two decades, Sangamo has built and validated the world’s largest library of ZFPs, deployin...

Read More

Industrial Impact

THE BRACKEN ORGANIZATIONS MERGE TO CREATE A GLOBAL PLATFORM TO SUPPORT LIFE SCIENCE AND DIGITAL HEALTH TEAMS

The Bracken Group | October 11, 2021

news image

Three unique companies with shared origins have now united to better serve their clients in the life sciences industry. The new entity will be known as The Bracken Group (Bracken) with three divisions of the original three companies. The combined companies' mission continues to be supporting the success of companies that improve health, using an integrated network of clients, consultants, and employees across the globe. I am delighted to bring the ...

Read More

YUFAN BIOTECHNOLOGIES AND ABOUND BIO SIGN MULTI-YEAR AGREEMENT TO DEVELOP NEXT GENERATION CAR T-CELL THERAPIES FOR CANCER

Yufan Biotechnologies | September 17, 2020

news image

Exhaustion of T-cells is a key reason why CAR T-cell therapy may fail to control cancer. Recent work led by Xuebin Liao, PhD, Professor of Pharmaceutical Science at Tsinghua University (Si et al., Cancer Cell 2020) shows that HPK1 (hematopoietic progenitor kinase 1) promotes T cell exhaustion via NFkB-Blimp1 activation and that blocking HPK1, either by gene knockout or by small-molecule inhibitors, is an attractive strategy to improve CAR T-cell immunotherapy. These innovative approaches a...

Read More
news image

MedTech

BIO-ISAC AND NEW YORK METRO INFRAGARD MEMBERSHIP ALLIANCE ANNOUNCE PARTNERSHIP

NY Metro InfraGard | April 28, 2022

The Bioeconomy Information Sharing and Analysis Center (BIO-ISAC) and New York Metro InfraGard Members Alliance® (NYM-IMA) today announced a partnership to address threats unique to the bioeconomy and enable coordination among stakeholders to facilitate a robust and secure industry. BIO-ISAC is a critical resource for cyber threat detection, prevention, protection, response, recovery and resilience in the bioeconomy. It helps spur the development and evaluation of defensive to...

Read More
news image

Industry Outlook

SANGAMO THERAPEUTICS AND CHROMA MEDICINE ANNOUNCE OPTION AND LICENSE AGREEMENT TO EVALUATE AND DEVELOP ZINC FINGER PROTEINS FOR EPIGENETIC EDITING

Businesswire | July 21, 2023

Sangamo Therapeutics, Inc. a clinical-stage genomic medicine company and Chroma Medicine, Inc. a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced they have entered into a research evaluation, option and license agreement to develop epigenetic medicines leveraging zinc finger proteins (ZFPs) for sequence-specific DNA recognition. Over the course of two decades, Sangamo has built and validated the world’s largest library of ZFPs, deployin...

Read More
news image

Industrial Impact

THE BRACKEN ORGANIZATIONS MERGE TO CREATE A GLOBAL PLATFORM TO SUPPORT LIFE SCIENCE AND DIGITAL HEALTH TEAMS

The Bracken Group | October 11, 2021

Three unique companies with shared origins have now united to better serve their clients in the life sciences industry. The new entity will be known as The Bracken Group (Bracken) with three divisions of the original three companies. The combined companies' mission continues to be supporting the success of companies that improve health, using an integrated network of clients, consultants, and employees across the globe. I am delighted to bring the ...

Read More
news image

YUFAN BIOTECHNOLOGIES AND ABOUND BIO SIGN MULTI-YEAR AGREEMENT TO DEVELOP NEXT GENERATION CAR T-CELL THERAPIES FOR CANCER

Yufan Biotechnologies | September 17, 2020

Exhaustion of T-cells is a key reason why CAR T-cell therapy may fail to control cancer. Recent work led by Xuebin Liao, PhD, Professor of Pharmaceutical Science at Tsinghua University (Si et al., Cancer Cell 2020) shows that HPK1 (hematopoietic progenitor kinase 1) promotes T cell exhaustion via NFkB-Blimp1 activation and that blocking HPK1, either by gene knockout or by small-molecule inhibitors, is an attractive strategy to improve CAR T-cell immunotherapy. These innovative approaches a...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us